Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to 13.2%.

  • Amphastar Pharmaceuticals' EBIT Margin fell 166400.0% to 13.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.73%, marking a year-over-year decrease of 88800.0%. This contributed to the annual value of 28.06% for FY2024, which is 25100.0% down from last year.
  • Amphastar Pharmaceuticals' EBIT Margin amounted to 13.2% in Q3 2025, which was down 166400.0% from 24.19% recorded in Q2 2025.
  • Amphastar Pharmaceuticals' EBIT Margin's 5-year high stood at 40.25% during Q3 2023, with a 5-year trough of 10.0% in Q1 2021.
  • Moreover, its 5-year median value for EBIT Margin was 23.88% (2023), whereas its average is 23.12%.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' EBIT Margin surged by 209200bps in 2023 and then crashed by -166400bps in 2025.
  • Amphastar Pharmaceuticals' EBIT Margin (Quarter) stood at 20.06% in 2021, then soared by 40bps to 28.02% in 2022, then increased by 8bps to 30.31% in 2023, then decreased by -20bps to 24.2% in 2024, then plummeted by -45bps to 13.2% in 2025.
  • Its EBIT Margin was 13.2% in Q3 2025, compared to 24.19% in Q2 2025 and 21.87% in Q1 2025.